Food and Drug Administration
May 13, 2003
Briefing Information
Disclaimer
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Atazanavir Briefing Document, Bristol-Myers Squibb Co. (PDF)
Reyataz™ (atazanavir sulfate) Capsules and Powder for Oral Use, FDA Review (HTM) (PDF) (Word)